Fibrillin-1 is a large structural protein that forms the backbone of tiny rope-like threads called microfibrils, found throughout nearly every tissue in your body. Encoded by the FBN1 gene on chromosome 15, it is best known as the protein behind Marfan syndrome, a genetic connective tissue disorder affecting the skeleton, eyes, and cardiovascular system. But fibrillin-1 does far more than provide scaffolding. Over the past two decades, researchers have discovered that it also controls growth factor signaling, anchors cells to their surroundings, and even gives rise to a hormone involved in blood sugar regulation.
What Fibrillin-1 Looks Like at the Molecular Level
Fibrillin-1 is enormous by protein standards. The gene that encodes it, FBN1, spans a large stretch of chromosome 15q21 and produces a precursor molecule called profibrillin, which is roughly 2,871 amino acids long. That precursor gets clipped by a specific enzyme before the mature protein takes its final shape. The mature form is sometimes described as a “mosaic” protein because it is built from repeating modular units strung together like beads on a chain. The dominant building blocks are 43 calcium-binding epidermal growth factor-like domains arranged as tandem repeats, interspersed with a second type of module known as TGF-beta binding protein-like domains.1PubMed. Solution structure and dynamics of a calcium binding epidermal growth factor-like domain pair from the neonatal region of human fibrillin-1 Both module types are stabilized by internal bridges formed from the amino acid cysteine, which lock each unit into a rigid shape.2PubMed. Fibrillin-1 misfolding and disease
Calcium plays a critical part in keeping these modules stiff. When calcium slots into its binding sites, the chain of domains resists bending and proteolytic attack. When calcium is absent, the protein becomes floppy and vulnerable to degradation. This is one reason why mutations that disrupt a calcium-binding site tend to cause more severe disease: the local region loses its rigidity and becomes an easy target for enzymes that chew up proteins.
The protein also contains an RGD motif, a short amino acid sequence recognized by cell-surface receptors called integrins, sitting within one of its TGF-beta binding protein-like domains.3PubMed Central. A disease-associated mutation in fibrillin-1 differentially regulates integrin-mediated cell adhesion That motif acts as a handshake between the microfibril and living cells, a feature that turns out to matter for everything from blood vessel development to wound healing.
How Microfibrils Are Built
Fibrillin-1 molecules do not simply drift together on their own. Their assembly into microfibrils depends on another extracellular protein, fibronectin. Experiments knocking down fibronectin in cultured cells showed that without fibronectin fibrils already in place, fibrillin-1 assembly essentially stalls.4PubMed Central. Fibrillin assembly requires fibronectin Early in the process, newly deposited microfibrils sit right alongside fibronectin strands, and blocking the cell-surface integrin receptors that drive fibronectin assembly also shuts down microfibril formation.5Journal of Cell Science. Fibrillin-1 microfibril deposition is dependent on fibronectin assembly In other words, cells orchestrate the whole process: they first lay down fibronectin, which serves as a template, and fibrillin-1 then latches onto it and begins to polymerize.
The C-terminal end of fibrillin-1 is particularly important here. Fibrillin-1 molecules multimerize through their C-terminal halves, and it is these multimers, not individual molecules, that interact strongly with fibronectin.6PubMed Central. Fibrillin assembly requires fibronectin Post-translational modifications also matter: a study of neonatal Marfan syndrome found that a single point mutation creating an extra sugar-attachment site on the protein severely disrupted microfibril formation in cultured fibroblasts, underscoring that the protein must be modified correctly to assemble properly.7PubMed. A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome
Recent cryo-electron microscopy has given researchers the first detailed look at what assembled microfibrils actually look like. The major bead region of the microfibril shows roughly eightfold symmetry, with both the beginning and end of the fibrillin-1 molecule meeting in that same bead.8PubMed Central. Fibrillin microfibril structure identifies long-range effects of inherited pathogenic mutations affecting a key regulatory latent TGFβ-binding site This structural detail helps explain how mutations far apart in the linear sequence of fibrillin-1 can still disrupt the same functional region once the protein folds into its three-dimensional microfibrillar arrangement.
Mechanical Roles in Tissues
Microfibrils serve as the scaffold onto which elastin is deposited during development. The resulting composite, called an elastic fiber, gives tissues like skin, lungs, and blood vessels the ability to stretch and snap back. Fibrillin-1 and elastin contribute differently to that process. Mechanical testing of mouse aortas has shown that elastin provides elastic recoil, the spring-like bounce, while fibrillin-1 microfibrils contribute tensile strength, resisting the tissue from being pulled apart.9PubMed Central. Discrete contributions of elastic fiber components to arterial development and mechanical compliance Lose fibrillin-1, and arteries become mechanically weaker even before elastin itself starts to fragment.
Beyond pure mechanics, fibrillin-1 microfibrils also serve as a communication hub. Through their RGD motif, they engage integrin receptors on the surface of endothelial cells, triggering signaling cascades that boost calcium levels inside cells, stimulate cell division, and promote cell migration.10PubMed. Microfibrils and fibrillin-1 induce integrin-mediated signaling, proliferation and migration in human endothelial cells This means fibrillin-1 is not passive scaffolding. It actively tells nearby cells what to do, a function that matters during blood vessel growth and tissue repair.
The TGF-Beta Connection
Perhaps the most consequential discovery about fibrillin-1 in the past twenty years is its role in controlling a potent growth factor called TGF-beta. Microfibrils physically trap TGF-beta in the tissue matrix by binding to latent TGF-beta binding proteins, essentially locking the growth factor in an inactive state until it is needed. When fibrillin-1 is deficient, this storage system breaks down and too much active TGF-beta floods the tissue.11Nature Genetics. Fibrillin controls TGF-β activation
This insight reframed how scientists think about Marfan syndrome. The older view was purely structural: without enough functional fibrillin-1, tissues simply fell apart. The newer view adds a signaling dimension. Excess TGF-beta actively drives tissue damage, promoting abnormal growth in bones, weakening blood vessel walls, and causing changes in the lungs. In mouse models, blocking TGF-beta with a neutralizing antibody or with the blood pressure drug losartan prevented aortic aneurysm formation, a landmark result that shifted therapeutic thinking.12PubMed Central. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome That said, subsequent work has shown the signaling picture is more nuanced. TGF-beta appears to play a protective role early in aortic disease and a harmful role later, suggesting that blanket suppression may not be ideal and that a combined approach targeting both TGF-beta and the angiotensin receptor pathway may be more effective.13PubMed Central. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome
Marfan Syndrome and the Cardiovascular System
Marfan syndrome is caused by mutations in FBN1 and inherited in an autosomal dominant pattern, meaning a single faulty copy is enough to cause disease. The syndrome’s most dangerous feature is progressive widening of the aorta, the body’s largest artery, which can lead to life-threatening tears called dissections. In fibrillin-1 deficient mouse aortas, elastin fragmentation is significantly increased, and the degree of fragmentation correlates directly with how much the vessel wall has stretched.14Circulation Reports. Aortic Strain Correlates With Elastin Fragmentation in Fibrillin-1 Hypomorphic Mice
Not all FBN1 mutations carry the same risk. Variants are broadly grouped into two types: those that cause haploinsufficiency, where the mutant copy simply fails to produce usable protein, and dominant-negative variants, where the mutant protein is made but interferes with normal fibrillin-1 function. A study tracking aortic outcomes in patients with Marfan syndrome found that those with haploinsufficient variants had roughly twice the risk of severe aortic events, including root replacement and type A dissection, compared to those with dominant-negative variants.15PubMed. Impact of Pathogenic FBN1 Variant Types on the Progression of Aortic Disease in Patients With Marfan Syndrome This finding has practical implications for genetic counseling and for deciding how aggressively to monitor or intervene surgically.
Circulating fragments of fibrillin-1 may eventually serve as a biomarker. Higher blood concentrations of fibrillin-1 fragments have been linked to thoracic aortic aneurysm, with the odds of having one roughly tripled in people whose fibrillin-1 fragment levels fell in the highest compared to the lowest quartile. The same elevated levels also predicted acute or subacute dissection.16PubMed. Thoracic aortic aneurysm frequency and dissection are associated with fibrillin-1 fragment concentrations in circulation If validated in larger studies, a simple blood test could one day help identify patients at heightened risk before a catastrophic event.
Eyes, Bones, and Beyond
Fibrillin-1 microfibrils form the tiny cables, called zonular fibers, that hold the lens of the eye in place. When fibrillin-1 is deleted specifically in the mouse eye, those fibers rupture by three months of age, causing the lens to slip out of position, a condition called ectopia lentis that is a hallmark of Marfan syndrome in humans.17PubMed Central. Targeted deletion of fibrillin-1 in the mouse eye results in ectopia lentis and other ocular phenotypes associated with Marfan syndrome Lens dislocation often turns up as one of the earliest recognizable signs, sometimes prompting an ophthalmologist to refer a patient for genetic testing before any cardiac symptoms appear.
The skeleton is another major target. People with Marfan syndrome tend to be unusually tall with disproportionately long limbs, fingers, and toes. Research in mouse models traced this overgrowth to the outer layer of the perichondrium, the tissue wrapping around developing bones. When fibrillin-1 is missing from that layer, latent TGF-beta binding proteins fail to accumulate, TGF-beta signaling drops locally, and the neighboring growth plate accelerates bone elongation. Adding TGF-beta back to mutant bones in culture normalized their length, confirming the connection.18PubMed Central. Fibrillin-1 deficiency in the outer perichondrium causes longitudinal bone overgrowth in mice with Marfan syndrome Interestingly, the skeletal story is essentially the mirror image of what happens in the aorta: in bones, the problem is too little TGF-beta at the growth plate, whereas in blood vessels, excess TGF-beta drives damage. This dual role makes treatment tricky, because a drug that dials down TGF-beta to protect the heart could worsen skeletal growth, and vice versa.
Diseases You Might Not Expect
Marfan syndrome is the best known FBN1-linked disorder, but it is not the only one. Certain mutations in a specific domain of fibrillin-1, known as the fifth TGF-beta binding protein-like domain, cause conditions that look nothing like Marfan syndrome. Weill-Marchesani syndrome, acromicric dysplasia, and geleophysic dysplasia all feature short stature and stiff joints, essentially the opposite of Marfan’s tall, flexible phenotype. The mutations responsible cluster in two regions that normally bind heparan sulfate, a sugar chain on cell surfaces. Mutant versions of fibrillin-1 carrying these changes showed significantly reduced heparan sulfate binding, disrupting normal microfibril interactions with surrounding cells and matrix.19PLoS ONE. Fibrillin-1 Mutations Causing Weill-Marchesani Syndrome and Acromicric and Geleophysic Dysplasias Disrupt Heparan Sulfate Interactions
A knock-in mouse model carrying one of these geleophysic dysplasia mutations in the same domain developed reduced stature, recapitulating the human phenotype. Both heterozygous and homozygous mutant mice showed disrupted growth plates, with chondrocytes failing to build a proper microfibrillar network.20Human Molecular Genetics. The critical role of the TB5 domain of fibrillin-1 in endochondral ossification The fact that one gene can produce both overly tall and overly short syndromes depending on which domain is hit is a striking example of how location within a protein determines the clinical outcome.
Asprosin and Metabolic Regulation
One of the more surprising chapters in the fibrillin-1 story started with a rare condition called neonatal progeroid syndrome, in which patients are extremely lean and have very little body fat. Researchers noticed that the mutations responsible all clustered near the very end of profibrillin, close to the site where the enzyme furin cleaves the precursor protein. That cleavage produces mature fibrillin-1 plus a small 140-amino-acid fragment from the C-terminus. This fragment, which had been ignored for years, turned out to be a previously unknown hormone. It was named asprosin.21Cell. Asprosin, a Fasting-Induced Glucogenic Protein Hormone
Asprosin is released by white fat tissue during fasting and travels to the liver, where it stimulates glucose production. People with neonatal progeroid syndrome, who carry mutations that prevent asprosin release from one copy of the gene, have abnormally low blood sugar and very little fat. At the other end of the spectrum, elevated asprosin levels have been linked to insulin resistance and obesity, sparking interest in the hormone as a potential therapeutic target for type 2 diabetes.22PubMed Central. Asprosin, a C-Terminal Cleavage Product of Fibrillin 1 Encoded by the FBN1 Gene, in Health and Disease That a gene primarily known for connective tissue disease also produces a metabolic hormone caught the field off guard and has opened an entirely new line of research.
How Fibrillin-1 Is Broken Down
Microfibrils are long-lived structures, but they are not permanent. A family of enzymes called matrix metalloproteinases can degrade both individual fibrillin-1 molecules and intact microfibrils. Studies using microfibrils isolated from the eye’s zonular fibers showed that several of these enzymes, including MMP-2, MMP-3, MMP-9, MMP-12, MMP-13, and MMP-14, caused gross disruption visible under electron microscopy.23PubMed Central. Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling Certain amino acid substitutions in fibrillin-1 changed the fragmentation patterns, meaning that some disease-causing mutations may make the protein not just structurally unsound but also easier for enzymes to chew apart. This double hit, structural weakness combined with accelerated degradation, could explain why some mutations lead to more rapid disease progression than others.
The relevance extends beyond genetic disease. Normal aging is accompanied by a gradual decline in elastic tissue throughout the body, and matrix metalloproteinases are prime suspects. Skin loses its elasticity, arteries stiffen, and the lungs become less compliant. All of these tissues depend on fibrillin-1 microfibrils, and the slow enzymatic erosion of those microfibrils over a lifetime is thought to contribute to the mechanical decline.
The Fibrillin Family and Evolutionary History
Fibrillin-1 is not alone. Mammals carry three fibrillin genes: FBN1, FBN2, and FBN3. Phylogenetic analysis suggests all three arose from a single ancestral gene through two rounds of duplication. The first duplication produced fibrillin-1 on one branch and a combined fibrillin-2/3 ancestor on the other. The second duplication, which coincides with the emergence of tetrapods, split that ancestor into fibrillin-2 and fibrillin-3.24PLoS ONE. The Evolution of Extracellular Fibrillins and Their Functional Domains Ray-finned fish, which diverged before that second event, still carry a combined fibrillin-2/3 rather than separate genes.
During development, all three fibrillins appear in broadly the same organs, but with telling differences at the tissue level, particularly in cartilage, the perichondrium, and developing airways.25PubMed Central. Fibrillin-3 expression in human development Fibrillin-2 is thought to play a larger role during early embryonic development and is associated with a separate condition, congenital contractural arachnodactyly. Fibrillin-3 remains the least studied. A complication for mouse research is that mice lack a functional Fbn3 gene entirely, which means they cannot fully replicate the human situation when it comes to potential compensatory roles among the fibrillin family members.26Genetics. Genetic models of fibrillinopathies
Experimental Therapies on the Horizon
Most current management of Marfan syndrome revolves around surveillance imaging of the aorta, blood pressure drugs, and preventive surgery when the aortic root reaches a critical diameter. But research is beginning to explore more targeted molecular approaches. One proof-of-concept study tested antisense oligonucleotides designed to skip a specific exon of the FBN1 gene during RNA processing. The idea is that if a harmful mutation sits in one exon, removing that exon entirely could produce a shorter but functional fibrillin-1 molecule, similar to the exon-skipping strategy used for Duchenne muscular dystrophy. In cultured fibroblasts, the approach achieved up to 100 percent skipping of the targeted exon. When skipping reached above 80 percent, fibrillin-1 fibers reappeared, suggesting the internally shortened protein could still assemble.27PubMed Central. Proof-of-Concept: Antisense Oligonucleotide Mediated Skipping of Fibrillin-1 Exon 52 This is still a long way from the clinic, but it represents a conceptual shift from managing downstream consequences to correcting the molecular defect closer to its source.
Limitations of Animal Models
Much of what we know about fibrillin-1 comes from mouse genetics, and those models have been invaluable. But they come with caveats. Mouse models of Marfan syndrome share some features with the human condition yet do not replicate the cardiovascular presentation completely. In some cases, heterozygous mice carrying one mutant Fbn1 copy look indistinguishable from normal mice, and only homozygous animals show disease, which does not match the dominant inheritance seen in humans.28Genetics. Genetic models of fibrillinopathies Skeletal differences between mice and humans, including bone size, growth plate closure timing, and the absence of Fbn3 in mice, further complicate translation. Researchers have to weigh findings from these models carefully, understanding that a drug that rescues a mouse aorta may not do the same thing in a human patient.